Wall Street analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post earnings of ($1.45) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($1.49) and the highest is ($1.42). Atara Biotherapeutics posted earnings of ($1.15) per share during the same quarter last year, which suggests a negative year over year growth rate of 26.1%. The business is expected to report its next quarterly earnings results on Wednesday, August 7th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.54) per share for the current financial year, with EPS estimates ranging from ($5.93) to ($5.21). For the next fiscal year, analysts anticipate that the company will report earnings of ($5.31) per share, with EPS estimates ranging from ($6.12) to ($4.63). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.48) by $0.04.

Several equities research analysts have recently weighed in on ATRA shares. ValuEngine lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 17th. Cowen reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. BidaskClub lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 22nd. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, Mizuho restated a “buy” rating and set a $62.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, May 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. Atara Biotherapeutics has a consensus rating of “Buy” and an average price target of $40.20.

In related news, CEO Isaac E. Ciechanover sold 5,850 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $23.09, for a total transaction of $135,076.50. Following the transaction, the chief executive officer now owns 332,243 shares in the company, valued at approximately $7,671,490.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $24.61, for a total value of $191,958.00. Following the transaction, the chief executive officer now owns 332,243 shares in the company, valued at approximately $8,176,500.23. The disclosure for this sale can be found here. Insiders have sold a total of 63,950 shares of company stock worth $2,220,035 in the last 90 days. 10.60% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in ATRA. FMR LLC grew its stake in shares of Atara Biotherapeutics by 21.7% in the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after purchasing an additional 1,143,787 shares during the last quarter. Redmile Group LLC grew its stake in shares of Atara Biotherapeutics by 1.6% in the 1st quarter. Redmile Group LLC now owns 4,485,417 shares of the biotechnology company’s stock valued at $178,295,000 after purchasing an additional 70,800 shares during the last quarter. BlackRock Inc. grew its stake in shares of Atara Biotherapeutics by 0.6% in the 4th quarter. BlackRock Inc. now owns 3,513,235 shares of the biotechnology company’s stock valued at $122,050,000 after purchasing an additional 22,453 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Atara Biotherapeutics by 53.8% in the 1st quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock valued at $76,237,000 after purchasing an additional 671,216 shares during the last quarter. Finally, Neuberger Berman Group LLC grew its stake in shares of Atara Biotherapeutics by 1.3% in the 1st quarter. Neuberger Berman Group LLC now owns 1,306,651 shares of the biotechnology company’s stock valued at $51,939,000 after purchasing an additional 16,703 shares during the last quarter.

Shares of NASDAQ ATRA opened at $23.32 on Friday. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. Atara Biotherapeutics has a fifty-two week low of $21.61 and a fifty-two week high of $50.90. The stock has a market cap of $1.03 billion, a PE ratio of -4.43 and a beta of 2.36.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: What do I need to know about analyst ratings?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.